377 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
offset by Opdivo and Revlimid.
U.S. revenues increased 7% to $8.5 billion primarily due to Eliquis, Reblozyl and Opdualag, partially offset by Revlimid … , partially offset by demand growth.
International revenues remained relatively flat at $3.4 billion primarily due to lower average net selling prices
DEFA14A
BMY
Bristol-Myers Squibb Co.
22 Apr 24
Additional proxy soliciting materials
8:16am
engaging in any speculative or hedging transactions, as we consider it improper and inappropriate to engage in any transactions that hedge or offset … , or are designed to hedge or offset, any decrease in the value of our securities. Our insider trading policy prohibits all employees, including directors
8-K
EX-99.1
apoo9zjhlckj
18 Mar 24
Strengthening Neuroscience Portfolio
8:56am
424B5
2v93ynadesfy ts
16 Feb 24
Prospectus supplement for primary offering
4:34pm
424B2
gcxr4r tzu8s
13 Feb 24
Prospectus for primary offering
8:00am
8-K
EX-99.2
kl2z zr9felrpp1y
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
8-K
EX-99.1
nyr 2kty0zf
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
SC TO-T
EX-99
9wol39aqasa7csboe
25 Jan 24
Third party tender offer statement
8:13am
DFAN14A
EX-99.1
309d juxtbdtemcvars
22 Dec 23
Additional proxy materials by non-management
4:21pm
8-K
EX-99.1
qlk6hs1pzc 44c
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
424B5
i6dl6r c65tam6
1 Nov 23
Prospectus supplement for primary offering
4:16pm
424B3
wip 29ku4jp00
30 Oct 23
Prospectus supplement
8:05am
8-K
EX-99.1
7jkr26nap1r
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.2
qtd0py976
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am